Treatment options for adenovirus infection in immunocompromised children are limited. Nephrotoxicity has been associated with cidofovir use, but the rate of cidofovir-associated nephrotoxicity in pediatric patients is unclear. In a retrospective review of patients with adenovirus infection treated with cidofovir, neonates (n = 5) had higher viral loads and shorter times to renal insufficiency than older children (n = 24). Higher weekly doses of cidofovir were associated with greater increases in creatinine levels. Of 29 courses of cidofovir, 9 were complicated by acute kidney injury; in these children, mortality was high. Cidofovir dosing in children needs to be optimized, and other therapeutic alternatives should be developed.
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Although adenovirus infection in a healthy host is generally self-limited and treatment is not required, the same virus in immunocompromised children can cause life-threatening multi-organ system disease. Adenovirus is an especially important pathogen in neonates [1] , children undergoing hematopoietic stem cell transplantation (HSCT) [2] [3] [4] , and solid organ transplant recipients [5, 6] . Antiviral therapy is often considered for these patients, although the efficacy of such treatment has not been proven.
Three currently available agents (ribavirin, ganciclovir, and cidofovir) have demonstrated in vitro efficacy against adenovirus. However, ribavirin and ganciclovir have shown limited to no therapeutic benefit in vivo [2] . Cidofovir, a nucleoside analog of cytosine that inhibits viral DNA polymerase, though not licensed for this indication, is currently the mainstay of antiviral therapy for adenovirus. The results of small studies and case reports support its use with some proven success in HSCT and solid organ transplant recipients [3, 4, [6] [7] [8] . Data on the treatment of adenoviral infection in neonates are even more limited. The mortality rate of neonates infected with adenovirus is extremely high, and few with disseminated disease survive, even with antiviral therapy [1, 9] . New antiviral agents, such as brincidofovir, a lipophilic conjugate of cidofovir, are undergoing clinical evaluation but are not yet available outside experimental protocols [10] .
Nephrotoxicity, including proteinuria, renal tubular acidosis, and renal failure, has been associated with the widely accepted dose (5 mg/kg of body weight, once per week for 2 weeks and then every other week) of cidofovir used in the treatment of cytomegalovirus (CMV) infection. Hyperhydration, along with coadministration of probenecid to increase serum concentration and decrease urinary secretion, is thought to provide some renal protection [4] . A modified dose regimen of 1 mg/kg 3 times per week, described by Hoffman et al [8] , seems to be somewhat less nephrotoxic [4, 11] . However, alterations in dosing due to renal dysfunction have been correlated with decreased viral suppression and poor clinical outcome [6, 11, 12] . The optimal dosing of cidofovir for adenovirus infection has not been established.
Although a retrospective survey of 10 European transplant centers found renal toxicity in 31% of cidofovir recipients [12] , most pediatric studies reported little or no toxicity with its use, regardless of dosing regimen [1, 3, 4, 6-8, 13, 14] . Pharmacokinetic data for children have been limited. A recent prospective study determined that the half-life of cidofovir is significantly longer in children than in adults [15] . We reviewed the use of cidofovir in a single pediatric hospital to help identify risk factors for toxicity and potential dosing approaches in immunocompromised children with adenovirus infection.
METHODS
All patients at Seattle Children's Hospital between December 2007 and March 2015 who had adenovirus detected in their blood by polymerase chain reaction and received cidofovir were included in this retrospective study after approval by the institutional review board. Each patient was in 1 of 2 cohorts, neonates (infants <28 days of age at time of viral detection) or older children. The incidence of acute kidney injury (AKI) and data on death, adenovirus viral loads, cidofovir dosing, infection with additional viruses, and presence of concomitant nephrotoxic medications were assessed. AKI was defined as an increase in the serum creatinine (SCr) level of ≥0.3 mg/dL from baseline or a requirement for continuous renal replacement therapy (CRRT), continuous venovenous hemofiltration, or hemodialysis at any time during cidofovir therapy. SCr data at baseline (within 72 hours of beginning therapy) and during cidofovir therapy were collected for each patient. Nephrotoxic medications for which data were collected included intravenous acyclovir, aminoglycosides, bumetanide, vancomycin, cyclosporine, ceftazidime, tacrolimus, sirolimus, intravenous contrast, furosemide, enalapril, epinephrine drip, lisinopril, and piperacillin-tazobactam.
A cidofovir dose of 1 mg/kg 3 times per week was generally used at our institution for patients with adenovirus infection. For some patients, particularly those with a higher viral load or concomitant CMV infection, 5 mg/kg per week with hyperhydration and probenecid for renal protection was used instead. The average weekly dose of cidofovir was calculated for each patient. A cidofovir course was defined as unique if administered >4 weeks after the previous dose in the same patient.
RESULTS
Overall, 28 children received 29 courses of intravenous cidofovir at various dosing regimens during the study period (Table 1) . One patient received 2 courses of cidofovir separated by 4 months.
The majority of patients in the group of older children received therapy after their HSCT. Additional nephrotoxic medications were frequent in both groups and most commonly included ceftazidime, vancomycin, intravenous acyclovir, angiotensin-converting-enzyme inhibitors, and calcineurin inhibitors.
Neonates received an average weekly cidofovir dose of 4.1 mg/kg with a median of 2 doses. Three infants received an initial dose of 5 mg/kg, whereas 1 infant received 1 mg/kg initially and then 4 mg/kg 2 days later. The remaining neonate received 1 mg/kg per dose 3 times per week for the duration of his course. Four of the patients in the neonate group received probenecid, but it is interesting to note that the 1 patient who did not was the only one in the cohort who did not develop renal insufficiency. This patient was also the only neonate who showed evidence of renal insufficiency before starting cidofovir.
Older children received a median of 3 doses, and the average weekly amount was 3.8 mg/kg. Seven patients initially received a dose of 5 mg/kg, whereas 16 patients received a lower dose of 1 mg/kg 3 times per week. Two patients in the lower-dose group were switched to 5 mg/kg dosing during their treatment course. One patient was given an initial weekly dose of 6.5 mg/ kg. In the older-children group, probenecid was given to 12 of the 24 patients, 2 of whom received it only after their dose was increased to 5 mg/kg. Of the 5 patients who developed renal insufficiency after receiving cidofovir, 3 had a previous history of renal insufficiency that dramatically worsened after the drug was administered. One of these patients was given 3 mg/kg per week, another was given 5 mg/kg per week, and the third patient's dose was increased from 3 mg/kg to 5 mg/kg after an increase in adenovirus copy numbers. Of the neonates and the older children, those who were given >3 mg/kg per week of cidofovir developed the largest increases in creatinine (Figure 1 ). In the neonate group, a median of 1 day from detection of adenovirus to treatment with cidofovir was documented. Neonates had significantly higher initial and peak viral loads than the older children. In total, 80% (4 of 5) of these young infants developed renal insufficiency; all of these infants eventually required extracorporeal membrane oxygenation (ECMO) and CRRT. The time to renal insufficiency was much shorter in the neonates than in the older children (median, 2 vs 20 days, respectively). The overall mortality rate in neonates and older children was almost 90% when renal insufficiency or failure was present (8 of 9).
Five patients, all from the older-children group, eventually had their antiviral therapy changed from cidofovir to brincidofovir. These transitions occurred at various time points; 2 patients had received 4 doses of cidofovir before being given brincidofovir, and 3 patients were switched after 1 dose of each. Four of these 5 children did not experience nephrotoxicity during their course and recovered from their adenovirus infection. The other patient developed AKI before the transition, and it continued to worsen while on brincidofovir.
DISCUSSION
In this study, we evaluated differences in viral loads, treatment, and outcomes between neonates and older pediatric patients treated with cidofovir therapy for systemic adenoviral infection. A significant rate of acute renal toxicity was documented, especially in the neonates. These young infants also had higher initial and peak viral loads, more rapid progression to renal insufficiency, a higher incidence of CRRT and ECMO, and a higher mortality rate (only 1 [20%] of the 5 neonates survived their infection). These results are consistent with those in the published literature, which indicate that neonates with disseminated adenovirus infection have a particularly poor prognosis [1] . Most striking was the mortality rate in the children who developed renal dysfunction; only 1 of these children survived. Although the severity of viral infection likely played the most significant role in these poor outcomes, the contribution of cidofovir and its resultant nephrotoxicity need to be explored. Furthermore, dosing strategies, especially in neonates, might require modification.
Cidofovir is the only antiviral agent currently available with some in vivo data that support its use for the treatment of severe adenovirus infection, although its efficacy has not been proven. Its use has been associated with substantial nephrotoxicity in adults. In multiple pediatric studies, renal injury was reported to be less significant than that in adults [1, 3, 4, 6-8, 13, 14] . Dosing regimens for children, especially neonates, have not been optimized. Pharmacokinetic data from Caruso Brown et al [15] indicate that cidofovir has a longer half-life in children than that seen in adults, and therefore children might be at higher risk for toxicity and/or require dose adjustment. No children younger than 2 years were included in their study, and pharmacokinetics data were examined after only 1 dose of cidofovir. Because our patients were given multiple doses of cidofovir, it is possible that this decreased clearance led to drug accumulation and nephrotoxicity.
In addition, it is likely that drug exposure was affected by the need for CRRT or ECMO, which can affect volume of distribution and clearance of drug. Drug levels were not measured, and in general, doses were not adjusted for CRRT or decreases in renal function. Only 1 of the 9 patients with renal insufficiency, a neonate, had the dosage modified from 5 mg/kg per week to a 1-time dose of 2 mg/kg. No additional doses were given, because the patient died 2 days later. A report of 1 adult patient's exposure to cidofovir while receiving continuous venovenous hemofiltration showed that drug clearance was reduced drastically, and the authors cautioned that repeat dosing might expose the patient to toxic levels of drug [16] . A better understanding of the effects of large circuits such as ECMO or CRRT on cidofovir clearance might help optimize dosing and decrease the potential for toxic exposures. Additional studies are necessary to develop age-appropriate dosing for cidofovir, especially in neonates and those with renal dysfunction.
Brincidofovir is an orally bioavailable investigational compound that has broad-spectrum antiviral activity. In a retrospective study of immunocompromised children and adults with severe adenovirus infection whose condition failed to improve with cidofovir, brincidofovir as salvage therapy was examined. Viral response was seen early and was sustained. Those authors found no serious adverse events attributed to the drug, including no significant change in renal creatinine clearance [17] . A recent study of CMV prophylaxis with brincidofovir in adult HSCT recipients did not find a statistically significant benefit, but the analysis was complicated by significant gastrointestinal disease in the brincidofovir recipients that was attributed to graft-versus-host disease [18] . Overall, 5 children in our study (none of them neonates) were switched from cidofovir to brincidofovir at various time points in their illness. Four of these patients did not develop AKI or significant gastrointestinal disease and survived their infection. One patient developed renal insufficiency while on cidofovir that continued to worsen after the transition to brincidofovir, and this patient eventually died. At this time, investigational studies of brincidofovir for the therapy of adenovirus infection are ongoing. This study was limited by being a single-center retrospective study with a small heterogeneous population. Proteinuria was not assessed as a marker of renal dysfunction, and pharmacokinetic studies were not performed. Baseline SCr values in the neonates might not have reflected true baseline levels, because most initial laboratory assessments occurred only after the infants were symptomatic with the viral infection, which itself can cause renal dysfunction. This lack of baseline data might have affected our ability to detect nephrotoxicity if renal function had been compromised already, or it might have predisposed the children to adverse effects of the drug. Three of the older patients had a history of renal insufficiency before receiving cidofovir. It is possible that this predisposed them to further damage. Despite these limitations, the rates of nephrotoxicity we witnessed are higher than those seen in most previously published pediatric study reports. It is clear that additional study of the treatment of adenovirus infection is required, especially in neonates. An alternative agent with limited adverse renal effects would be an important addition to the therapeutic options available when treating severe adenovirus infection in immunocompromised children.
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